Physician profile
Paul Eugene Brown
NPI 1659355774
$17,031.61
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,410 · 2020: $2,462 · 2021: $3,102 · 2022: $3,519 · 2023: $2,808 · 2024: $2,731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,502 · Education: $37.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,501.69 |
| Education | $37.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,160.49 | 2019-2024 | Xifaxan, Trulance, Relistor |
| Abbvie INC. | $3,080.02 | 2019-2024 | Linzess, Viberzi, Skyrizi |
| Takeda Pharmaceuticals U.S.A., INC. | $2,503.52 | 2019-2024 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $2,289.07 | 2019-2024 | Stelara, Tremfya |
| Pfizer INC. | $713.47 | 2019-2024 | |
| Ferring Pharmaceuticals INC. | $608.33 | 2019-2023 | Rebyota, Cimzia |
| Ironwood Pharmaceuticals, INC | $500.30 | 2020-2024 | Linzess |
| Merck Sharp & Dohme LLC | $451.13 | 2019-2024 | Dificid |
| Qol Medical, LLC | $389.06 | 2019-2024 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $358.84 | 2022-2024 | Dupixent |
| Ardelyx, INC. | $288.49 | 2023-2024 | Ibsrela |
| Genzyme Corporation | $282.40 | 2022-2024 | |
| Celgene Corporation | $281.88 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $268.73 | 2019-2024 | |
| Ucb, INC. | $263.06 | 2019-2020 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $219.35 | 2019-2024 | Ocaliva |
| Redhill Biopharma INC. | $152.97 | 2020-2023 | Talicia |
| Amgen INC. | $96.48 | 2021-2023 | Avsola, Amjevita |
| Allergan, INC. | $91.22 | 2020 | |
| Organon LLC | $89.93 | 2021-2024 | Hadlima, Renflexis |
| Csl Behring | $82.23 | 2020-2021 | |
| Aimmune Therapeutics, INC. | $80.51 | 2024 | |
| Fresenius Kabi USA, LLC | $77.26 | 2023-2024 | Idacio |
| Phathom Pharmaceuticals, INC. | $74.65 | 2024 | Voquezna |
| Evoke Pharma, INC. | $70.67 | 2022 | |
| Daiichi Sankyo INC. | $67.88 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $66.79 | 2022-2023 | |
| Shire North American Group INC | $58.71 | 2019 | |
| Albireo Pharma, INC. | $55.45 | 2024 | Bylvay, Iqirvo |
| Novo Nordisk INC | $53.43 | 2024 | Wegovy |
| Boston Scientific Corporation | $53.25 | 2024 | Watchman Access System, Watchman Flx |
| Braintree Laboratories, INC. | $50.45 | 2019-2024 | Suflave |
| Lilly USA, LLC | $31.36 | 2024 | Omvoh, Zepbound |
| Sandoz INC. | $20.73 | 2024 | Hyrimoz |
| Ipsen Biopharmaceuticals, INC | $20.00 | 2024 | Iqirvo |
| Celltrion USA INC. | $17.00 | 2024 | Zymfentra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.05 | 2024 | Cyltezo |
| Shionogi INC | $13.38 | 2019 | |
| Acacia Pharma INC | $13.32 | 2021 | |
| Alfasigma USA, INC. | $12.80 | 2021 | |
| Micro-Tech Endoscopy USA, INC. | $6.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.